Allegheny General Hospital in Pittsburgh has opened enrollment for patients in its new clinical study to examine the safety and efficacy of an investigational Clostridium difficile vaccine.
Allegheny General is one of more than 200 sites across 17 countries around the world involved in the C. diff vaccine clinical trial, a Phase III randomized, observer-blind, placebo-controlled study.
Patients interested in enrolling in the study should be age 50 or older and planning an upcoming hospitalization of more than 72 hours for a surgical procedure. Also eligible for the study are patients in this age group who have been hospitalized at least twice, each time lasting more than 24 hours, and have received systemic antibiotics in the past year.
For more information about how to enroll, click here.
More articles on C. diff:
How South Seminole Hospital cut C. diff infections in half
10 recent stories, studies on C. diff
A non-antibiotic drug could work against C. diff, study finds